z.B. 10/08/2024
z.B. 10/08/2024

bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1), a test for improved assessment of patients with mild traumatic brain injury

23 Oktober, 2023

Marcy-l’Étoile, France – October 13th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*. This accurate and objective tool can help reduce the number of unnecessary head Computed Tomography (CT) scans performed for mTBI patients and to decrease Emergency Department (ED) overcrowding by predicting the absence of acute intracranial lesions (ICL) following a head trauma.

Pioneering diagnostics